Erik Helding
Analyst · Wells Fargo Securities
Thanks, Gary. CNO posted another strong quarter on the earnings and capital fronts. We reported net income of $0.36 per share, up 44% from the prior year. Operating earnings per share was $0.34, up 26% from the prior year. First quarter 2017 results were impacted by favorable underwriting margins and investment results, partially offset by higher expenses due to a true-up of our guaranteed fund assessment liability related to the Penn's Treaty and solvency proceedings. Excluding significant items, net operating earnings per share was $0.35, up 35% from the prior year, and operating return on equity was 8.8%. Turning to slide 11, our segment results. CNO posted combined EBIT excluding significant items of just over $107 million in the quarter, up 27% from the prior year. Results in the quarter reflect favorable annuity, long-term care and Medicare Supplement margins at Bankers Life; lower supplemental health margins at Washington National; favorable mortality and lower direct marketing spend at Colonial Penn; and higher corporate segment expenses that were partially offset by higher investment income. Lastly, our closed block LTC business reported approximately breakeven earnings, in line with our expectations. Turning to slide 12 and our key health benefit ratios. Bankers Life Medicare Supplement benefit ratio was 70% in the quarter, slightly better than expectations due to favorable incurred claims. We continue to expect this ratio to be in the 71% to 74% range during 2017. Bankers Life long-term care interest adjusted benefit ratio, excluding the impact of rate increases, was 74.2%, better than expectations due to lower persistency and favorable incurred claims. It's also worth noting that the first quarter 2017 interest adjusted benefit ratio reflects no additional future loss reserve accrual as a result of the increased loss recognition testing margins we reported in the fourth quarter of 2016. We continue to expect this ratio to be in the 77% to 82% range during 2017. Washington National supplemental health interest-adjusted benefit ratio was 60.6%, up compared to the prior year due to higher incurred claims but in line with our expectations. We continue to expect this ratio to be in the 58% to 61% range during 2017. Turning to slide 13 and our investment results for the quarter. We put money to work at 5.23%, somewhat higher than the previous quarter, largely related to duration extension trades to improve our ALM matches in lines of business with longer duration liabilities. Call prepayment activity was muted in the quarter due to the relatively lower levels of refinancing activity. We experienced solid alternative investment results as we benefit -- benefited from allocation to income-based strategies and higher overall equity markets. Realized gains, losses and impairments continue to be moderate, and we continue to make progress in repositioning the recaptured assets. As of March 31, we had approximately $88 million with assets remaining, down from $121 million at year-end. Turning to slide 14 and our capital position. Estimated consolidated risk-based capital was 446%, down from year-end, but within our targeted range. Results reflect approximately $70 million of statutory income, offset by dividends of the holding company of $128 million. Leverage was steady at 19.1%. Book value per diluted share was up $22.31, up slightly from year-end and up almost 10% on a year-over-year basis. Holding company cash and investments was $314 million, up from $264 million at year-end, due primarily to the previously-mentioned insurance subsidiary dividends. We repurchased $43 million of common stock in the quarter, at somewhat lower levels reflecting the resumption of the buyback program in mid-February and the stock price that was elevated for much of the second half of the first quarter. For 2017, we continue to expect to repurchase $200 million to $275 million of common stock, absent compelling alternatives. We are quite sensitive when it comes to repurchasing our stock, and the absolute level of repurchases and where we end up within the range, will depend on the share price as we make our way through the year. And with that, I'll turn the call back over to Ed.